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Summary A ‘stent’ is a tubular meshed endoprosthesis that has contributed to the devel-
opment of interventional catheterization over the past 30 years. In congenital heart diseases,
stents have offered new solutions to the treatment of congenital vessel stenosis or postsurgi-
cal lesions, to maintain or close shunt patency, and to allow transcatheter valve replacement.
First, stents were made of bare metal. Then, stent frameworks evolved to achieve a better
compromise between radial strength and ﬂexibility. However, almost all stents used currently
in children have not been approved for vascular lesions in children and are therefore used
‘off-label’. Furthermore, the inability of stents to follow natural vessel growth still limits their
use in low-weight children and infants. Recently, bioresorbable stents have been manufactured
and may overcome this issue; they are made from materials that may dissolve or be absorbed
in the body. In this review, we aim to describe the history of stent development, the tech-
nical characteristics of stents used currently, the clinical applications and results, and the
latest technological developments and perspectives in paediatric and adult congenital cardiac
catheterization.
© 2014 Elsevier Masson SAS. All rights reserved.
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Résumé Un stent est une endoprothèse maillée tubulaire qui a contribué à l’essor du
cathétérisme interventionnel sur les trente dernières années. En cardiologie pédiatrique et
congénitale, les stents ont offert de nouvelles solutions pour traiter des sténoses congénitales
des vaisseaux ou des lésions postopératoires, pour maintenir ou occlure la perméabilité d’un
shunt et pour permettre le remplacement valvulaire par voie percutanée. À l’origine, les stents
étaient formés d’une structure métallique « nue ». Puis plusieurs structures de stents ont été
dessinées pour un meilleur compromis entre force radiaire et ﬂexibilité. Néanmoins, la plu-
part des stents actuellement utilisés n’ont pas été développés pour les lésions congénitales
de l’enfant et sont utilisés « off-label ». De plus, l’incapacité des stents à suivre la crois-
sance naturelle des vaisseaux limite leur usage chez les enfants de faible poids et chez les
nourrissons. Des stents biorésorbables ont récemment été développés avec la capacité d’être
dégradés par l’organisme. Dans cette revue générale, nous avons souhaité décrire l’historique
de développement des stents, les caractéristiques techniques des stents actuellement util-
isés, les applications cliniques et les résultats, les dernières évolutions technologiques et les
perspectives dans le domaine des cardiopathies congénitales.
© 2014 Elsevier Masson SAS. Tous droits réservés.
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Since the ﬁrst report of transcatheter balloon dilation
of pulmonary stenosis in 1953 [1], balloon angioplasty
has been widely used for many valvular and vascular
congenital lesions [2—5]. However, ineffective relief of
obstruction and vessel damage have been observed [3—5].
A ‘stent’ is a tubular meshed endoprosthesis that has con-
tributed to overcoming these issues [4,6—8]. In this general
review, we will ﬁrst describe the pioneering reports of
stents development. Next, we will investigate the techni-
cal aspects of the available stents. Concepts sustaining the
use of stents in congenital heart disease (CHD) catheteri-
zation, as well as clinical applications and complications,
will be underlined. Finally, future directions will be dis-
cussed.Historical background
The origins of the word ‘stent’ remain controversial; it may
be an old English word derived from the verb ‘stenten’.
o
i
e
uhe Latin root is ‘extendere’, meaning to stretch out. Con-
ersely, the word may have been ﬁrst used in 1916 by
an F. Esser, a Dutch plastic surgeon, to describe a medi-
al prosthesis created by an English dentist, Charles Stent
1807—1885) [9]. In 1964, Charles Dotter suggested that
n implantable prosthetic device might be used to main-
ain the luminal integrity of diseased vessels. A precursor
tent was successfully positioned in femoral dog arteries,
ut with secondary dislocations and narrowing [10]. There-
ore, it was not until the early 1980s that stents regained
nterest, with a self-expandable stent with a memory-of-
hape property [11]. The ﬁrst human intracoronary stent
WallstentTM; Boston Scientiﬁc, Natick, MA, USA), made
f a self-expandable stainless-steel mesh, was successfully
eployed in coronary arteries by Jacques Puel in 1986 in CHU
oulouse [12].
Stents rapidly increased interest in the interventional
reatment of CHD. In the mid-1980s, Julio C. Palmaz devel-
ped a balloon-expandable stent that was successfully
mplanted in various locations in 1991 [8]. Later, in the
arly 2000s, Philipp Bonhoeffer and Younes Boudjemline
sed a stent as a support to anchor a valve in a right
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entricle-to-pulmonary artery (RV-to-PA) prosthetic conduit
ith valve dysfunction [13].
The ﬁrst stent available for use in children was
he balloon-expandable closed-cell design PalmazTM stent
Johnson & Johnson Interventional Systems, Warren, NJ,
SA) [8]. Since then, many others stents have been
eveloped, including the GenesisTM stent (Johnson &
ohnson Interventional Systems, Warren, NJ, USA) [14],
he Cheatham-PlatinumTM (CP) stent (NuMED, Hopkinton,
Y, USA) [15], the IntraStentTM DoubleStrutTM stent (eV3
nc., Plymouth, MN, USA) [16] and others. Today, the most
ommonly used stents are the series of eV3 stents (eV3
nc., Plymouth, MN, USA), the CP stent [17], the ValeoTM
tent (Bard Peripheral Vascular, Tempe, AZ, USA) and valved
tents (Melody® valve, Medtronic Inc., Minneapolis, MN,
SA; Edwards-SapienTM Valve, Edwards Lifesciences LLC,
rvine, CA, USA) [13,18—21]. New stents have emerged
ith promising results in CHD catheterization, such as the
ndrastentTM stent (Andramed, Reutlingen, Germany) and
he FormulaTM stent (Cook Europe, Bjaeverskov, Denmark)
22,23]. Almost all stents used currently in children have
ot been approved for vascular lesions in children and are
sed ‘off-label’.
tent design
tents are categorized according to mechanism of deliv-
ry, composition, conﬁguration, size and properties. Stent
erformance depends on material characteristics, form,
abrication mode and geometry. Performances of stents used
n CHD are described in eTables 1—3 in the online-only data
upplement.
tent delivery mechanism
wo stent delivery mechanisms are available. Stents are
alloon-expandable or self-expandable. In the balloon-
xpandable system, the stent is crimped manually onto
balloon or premounted by the manufacturer. The bal-
oon catheter stent is moved forward on an intravascular
uidewire through a long sheath. The stent is then deployed
n the area of interest by inﬂating the balloon. The stent
nal diameter is determined by the inﬂated balloon diam-
ter. The balloon inﬂation allows a high radial force during
tent implantation to relieve vascular obstruction. Postdi-
ation with a larger balloon is possible to further increase
tent diameter [24].
Premounted stents, due to superior nesting to the bal-
oon, have a lower proﬁle and do not require long and large
heaths, enhancing their ‘trackability’ in reaching tortuous
estinations and facilitating their use in small children. In
A stenting, the use of premounted stents seems to be asso-
iated with fewer complications [25]. The balloon plays a
ivotal role in the success of the stent positioning. The
alloon-In-Balloon catheter (BIB®; NuMED, Hopkinton, NY,
SA) was speciﬁcally designed for medium-to-large stent
elivery. The inner smaller balloon is inﬂated ﬁrst, partially
xpanding the stent without ﬂaring, and allows reposition-
ng of the stent before ﬁnal deployment, when the outer
alloon is inﬂated (Figs. 1 and 2; Video 1) [15]. Balloon-
xpandable stents, premounted or not, should always be
f
v
m
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elivered through a long covering sheath. The covering
heath facilitates stent positioning control and prevents
nvoluntary uncrimping.
The EnsembleTM system (Medtronic Inc., Minneapolis, MN,
SA) was speciﬁcally developed to facilitate introduction,
elivery and deployment of the balloon-expandable Melody
alved stent; it incorporates a BIB balloon and a mecha-
ism with a covering sheath to protect the valve as it is
dvanced through the right ventricular outﬂow tract (RVOT)
Figs. 3 and 4; Video 2). Balloon-expandable stents have
foreshortening phenomenon during inﬂation. The degree
f foreshortening depends on the stent conﬁguration and is
aximal at larger diameters. Stent foreshortening must be
nticipated before delivery to be certain that it will com-
letely cover the treated lesion.
Self-expandable stents are constrained by a covering
heath. After positioning in the area of interest, the covering
heath is withdrawn and the stent regains its original shape
26]. Self-expandable stents are made of an alloy of nickel
nd titanium, with a memory-of-shape property, but with
ess radial strength than most balloon-expandable stents
nd therefore a higher risk of vessel recoil. Once in place,
urther expansion of the self-expandable stent is not possi-
le, unlike balloon-expandable stents, which can be further
ilated at a later time [24]. This property is essential in
mall children with growing vessels. Many interventionists
ave advised against the use of self-expandable stents in
rowing children [25].
omposition
tents are mostly made of metals, allowing high radial
trength. Stainless steel is resistant to corrosion and is eas-
ly deformable. Cobalt chromium alloys may allow lower
rimping proﬁles with high radial strength. Stents made with
etal get incorporated into the vessel wall and do not have
he potential to grow or to be degraded by the organism.
variety of degradable materials have been studied for
iodegradable stent design, including polyesters, polycar-
onates, bacterial-derived polymers and corrodible metals
uch as magnesium and iron [27].
onﬁguration
wo types of stent frameworks have been designed. The
slotted-tube’ design means that the stent is formed from a
nique stalk cut by laser from a tube. Premounted stents are
ut in the crimped position, allowing a low proﬁle. The other
tent framework consists of multiple circular stalks repeat-
dly curved as a crown and linked by connectors. The stent
s manufactured from a wire, which is bent and welded to a
ylindrical meshwork; this leads to more adjustable ﬂexibil-
ty and wide size and length ranges, but the radial strength
s usually less than that for stents with slotted tubes.
In an ‘open-cell’ design, geometry does not connect
onsistently throughout the stent, forming incomplete and
on-bridged cells. With expansion, the individual cells
erge to form larger open areas. This type of stent has lessoreshortening, good conformability and ﬁts well in curved
essels. Depending on the curve of the stent, the cell area
ay vary. In vessel bifurcation stenting (PA bifurcation, aor-
ic arch), the perfusion of a jailed side branch is unlikely
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Figure 1. A. A 15-year-old girl with a native aortic coarctation. B. CP8Z39 stent manually crimped onto a Balloon-In-Balloon catheter
. C.
tery.
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pballoon (diameter 14mm) and positioned through the coarctation
balloon inﬂation. F. Final result. Ao: aorta; LSCA: left subclavian ar
to be altered with an open-cell stent. If it happens, a bal-
loon reopening of the struts (‘kissing’) will be easier with
this type of stent and with the low number of connectors
(Figs. 4 and 5; Video 2).
Alternatively, a stent with many connectors, such as the
CP stent, is called a ‘closed-cell’ stent. It has a high radial
strength and a high vessel scaffolding area, regardless of the
degree of bending. A high scaffolding area allows better pro-
tection of a vessel with a parietal tear and prevents parietal
tissue hernia between the stent struts.
Covered stentsSome stents are covered by a membrane. Covered stents
were originally developed to seal perforated and ruptured
arteries. The primary use of covered stents in CHD has been
advocated in subatretic coarctation [4], native coarctation
p
t
s
tand D. Inner balloon inﬂation and angiographic control. E. Outer
ssociated with patent ductus arteriosus and coarctation
ombined with aneurysm [7]. Covered stents should not jail
essels, leading to anterograde ﬂow obstruction.
tent properties: characteristics of the ideal
tent in congenital heart disease
ifteen particular stent properties are expected for maxi-
al performance and are summarized in Table 1. Currently
vailable stents do not have all these requirements. As in a
ugby team, in which wingers run faster but are weaker than
illars, the choice of stent will be a compromise between
riorities and expected properties. The choice integrates
he age and size of the patient, the expected adult dimen-
ions of the vascular structure, the morphology of the lesion
o treat and expected future surgical procedures.
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Figure 2. A. A 10-year-old girl with type 2 troncus arteriosus and postsurgical right pulmonary artery (RPA) stenosis. B. and C. IntraStent
Max LD 26-12 stent manually crimped onto a Balloon-In-Balloon catheter balloon (diameter 12mm) and positioned along the elastic stenosis
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py removal of the introducing sheath. D. Inner balloon inﬂation and
n the outer balloon than in the inner balloon. F. Final result. LPA: l
oncepts sustaining the use of stents in
ongenital heart disease
tent clinical applications in catheterization of CHD are sum-
arized in Table 2 and follow recommendations [28].
tenting to increase the efﬁciency of balloon
ngioplasty
alloon angioplasty is used to release vascular obstruction,
uch as PA stenosis. Balloon angioplasty alone is success-
ul in 60—80% of PA branch angioplasty [5]. Ineffective
elief of obstruction results from resistant non-compliant
esions [29] or elastic recoil of the vessel wall. Resteno-
is also occurs as a result of external compression, intimal
ears and natural vessel growth out of the angioplasty zone
5]. Stents exert radial forces that prevent elastic recoil
Figs. 2, 4 and 5; Video 2) [8]. Intravascular stenting provides
uperior gradient relief and angiographic results compared
ith conventional balloon angioplasty alone in various con-
enital vascular lesions [4,30]. Success rates in studies using
tents and cutting balloons or high-pressure balloons in
ulmonary stenosis and RV outﬂow conduit stenosis rise
o > 90% [29,31]. Stents are used in around 40% of cases
f PA angioplasty [32] and are sometimes used as ﬁrst-
tep intervention without balloon angioplasty. Transcatheter
tent implantation can acutely relieve congenital or
o
p
v
tographic control. E. Outer balloon inﬂation: contrast more diluted
ulmonary artery.
ostoperative pulmonary vein stenosis in children, but
eintervention is common. Larger stent lumen size at
mplantation is associated with longer stent patency and a
ower risk of reintervention [33]. Nowadays, with aggressive
alloons and stents, successful relief of congenital vascular
tenosis is effective in almost all cases.
tenting to increase the safety of balloon
ngioplasty
alloon angioplasty can be complicated by intimal tears,
essel dissection and vessel rupture, particularly during
ative aortic coarctation dilation [3,4,32]. Intravascular
tenting enables scaffolding that compresses dissection ﬂaps
gainst the vessel wall and provides a substrate for smooth
eointimal growth. In transcatheter treatment of native
ortic coarctation (Fig. 1; Video 1) and recoarctation, pri-
ary stenting compared with balloon angioplasty prevents
ong-term adverse effects of vessel remodelling, leading to
estenosis and pseudoaneurysm formation [2,4,7]. Rescue
tenting is also performed in RVOT and PA branch angio-
lasty if balloon angioplasty is complicated by tear with ﬂow
bstruction or pseudoaneurysm [29,32]. Primary stenting is
referred over balloon angioplasty in early postoperative
ascular lesion dilation to prevent fresh suture line disrup-
ion [34]. Covered stents are used in emergency situations
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Figure 3. A 29-year-old woman with corrected pulmonary valve agenesis and ventricular septal defect (A). Transcatheter pulmonary
revalvulation indicated by dilated right ventricle due to severe pulmonary regurgitation. Prestenting of the pulmonary annulus, with CP8Z45
er 22
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Pstent crimped onto a Balloon-In-Balloon catheter balloon (diamet
(22mm) into landing zone (B and D). LPA: left pulmonary artery; RP
to rescue perforated vessels; the outer membrane provides
excellent sealing of the damaged vessels.
Stenting to occlude shunt
Covered stents provide a physical barrier between the ves-
sel lumen and the vessel wall, which is useful to occlude
shunt patency, such as fenestrated total cavopulmonary con-
nection (Fig. 5) [35], Mustard bafﬂe leaks (Fig. 6) [36],
persistent ductus arteriosus associated with aortic coarcta-
tion [7] or Potts shunt [37].
Stenting to maintain shunt patency
In neonates with a duct-dependent pulmonary circulation,
the surgical creation of an aortopulmonary shunt is recom-
mended if early repair is not feasible to palliate duct natural
occlusion. Ductus arteriosus stenting was developed as an
alternative option to prevent surgery-related morbimortal-
ity [38,39] with similar efﬁcacy [40]. Stents are also used
to relieve Blalock-Taussig shunt obstruction [41]. Palliative
stenting of patent ductus arteriosus may also be performed
in older children and in adults with suprasystemic pulmonary
arterial hypertension [42]. A hybrid procedure with ductus
arteriosus stenting and bending of the PAs is under investiga-
tion as an alternative to Norwood surgery perfusion in infants
with hypoplastic left heart syndrome (Fig. 7; Video 3) [43].
Stenting of the interatrial septum after atrial septostomy
is also performed occasionally in selected neonatal cases,
[
o
r
amm) (B). Melody valve (C) implanted through Ensemble system
ht pulmonary artery; RVOT: right ventricular outﬂow tract.
nd even in foetal cases, to maintain reliable long-lasting
nteratrial communication [44].
tenting as a support for percutaneous valve
eplacement
ranscatheter valve replacement became feasible by insert-
ng a bovine jugular vein into an expandable stent, and was
pplied primarily to the pulmonary valve [13]. A balloon-
xpandable stent is used as a support to anchor and deploy
he valve in the target position. Bare stenting of the RVOT
eads to free pulmonary regurgitation. A valved stent allows
reatment of both RVOT obstruction and pulmonary regurgi-
ation [13,18]. Recoil and fracture of the valved stent have
een reported [45]. Thus, conventional stents are also used
s a ‘prestenting’ procedure in the ‘landing zone’ of the
ranscatheter pulmonary valve replacement. The prestent-
ng strengthens the landing zone before valve deployment
Figs. 3 and 4; Video 2) [45].
ybrid approach
tenting has become an alternative to a variety of surgi-
al interventions, such as in aortic coarctation treatment,
ith less morbidity [4]. In other cases, such as RV-to-
A obstruction, stenting allows postponement of surgery
22,46,47]. Furthermore, a hybrid approach has been devel-
ped, combining step-by-step surgery and stenting, as in
ehabilitation of PAs in tetralogy of Fallot with pulmonary
tresia and major aortopulmonary collaterals (Fig. 8) [48].
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Figure 4. A 15-year-old boy with type 2 corrected tetralogy of Fallot with pulmonary atresia. Right ventricle (RV)-to-pulmonary artery (PA)
conduit (Contegra; 20mm) highly restrictive with bilateral ostiale pulmonary artery stenosis (A). IntraStent Max LD 36-12 stent implanted
from the main PA to the right PA (RPA) with reopening of the stitches to the left PA (LPA) (B and C). Second IntraStent Max LD 36-12 stent
implanted into the conduit to increase landing zone radial stiffness (D). Melody valve implanted into Ensemble delivery system (22mm)
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tE—G). Note the difference in radiopacity between the Cheatham-P
hybrid procedure combining surgery and stenting is also
erformed concomitantly in the operating room in selected
ases [43].
tenting complications in congenital heart
isease
omplications occur in 3.5—19% of cases [25,32,49],
esulting in a 2.3% overall procedural mortality [25]. Compli-
ation rates are highly dependent on the location of stenting
25]. Arterial duct stenting remains a challenging interven-
ion [25]. Many complications during stent implantation are
ransient and can be solved without ending the procedure;
thers may be solved by surgery [50]. Thus, catheteriza-
ion of CHD with stent implantation should be performed
n specialized centres with congenital cardiac surgery. Fur-
hermore, the rate of complications is related to the degree
f operator experience [51]. Stent implantation should be
erformed by highly experienced hands.
a
d
a
Aum and IntraStent stents (E and F).
arly embolization and migration
tent malpositioning, migration and early embolization are
ependent on operator experience [32]; they are the most
requent complications, occurring in 7.7% of all implanta-
ions [25].
eointimal proliferation and restenosis
estenosis seems to be rare, occurring in < 2% of cases [24].
peciﬁc risk factors are stent malpositioning, over-dilation
nd abnormal underlying vascular tissue [24]. Neointimal
roliferation is less frequent (around 4%) with a balloon-
xpandable stent than with a self-expanding stent (around
8%). However, the restenosis rate seems to differ according
o stent location. In PA stenting, a recent report identiﬁed
restenosis rate as high as 25%, with the highest inci-
ence among patients with tetralogy of Fallot and multiple
ortopulmonary collaterals (Fig. 8), Williams syndrome or
lagille syndrome [6,52].
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Figure 5. A. A 41-year-old woman with repaired tetralogy of Fallot and pulmonary atresia had stenosis of both pulmonary arteries. B.
IntraStent Max LD 36-12 stent positioned on the right pulmonary artery (RPA); CP8Z34 stent and IntraStent Max LD 36-12 stent positioned on
the left pulmonary artery (LPA). C. and D. Right superior lobar artery (RSLA) perfusion altered by stent jailing and improved after reopening
of the stent stitches by a kissing balloon.
Table 1 Stent properties: characteristics of the ideal stent in congenital heart disease interventional catheterization.
1 Radiopacity High radio-opacity facilitates stent positioning before implantation
2 Low proﬁle A stent with a low proﬁle decreases the delivery sheath size
3 Good crimpability Premounted stents or easy hand crimping with stability of the stent onto the
delivery balloon are expected
4 High ﬂexibility High ﬂexibility allows delivery in tortuous vessels like pulmonary arteries, gives
compliance to the target area and ease of manoeuvrability during deployment
5 Good conformability A stent with good conformability will ﬁt well with the vessel geometry and curves,
and will protect from vessel distortion
6 No foreshortening A predictable expansion diameter with a low degree of stent foreshortening is
expected during stent expansion for precision of positioning and to better match
the length of lesion to be treated
7 High radial strength Stents must have a high radial strength to resist external radial forces of the vessel
wall, prevent vessel recoil and keep tight and scarred lesions open
8 High scaffolding High scaffolding of the vessel is necessary to prevent parietal tissue protrusion and
risk of restenosis
9 Retrievability Stent retrievability and repositioning decrease the risk of malpositioning and
embolization
10 Wide struts Wide struts are expected to maintain blood ﬂow to jailed vessel branches
11 Soft edges Rounded and soft edges will prevent vascular tears and balloon rupture during
delivery
12 Potential to grow An ideal stent implanted in small children would follow the natural growth of the
vessel; on the other hand, a stent must be redilatable until the expected adult
diameter is reached
13 Solidity The framework must be solid enough to resist fracture; loss of integrity decreases
the radial strength and increases the risk of restenosis
14 Imaging
compatibility
The stent should be compatible with all imaging modalities without artefacts
15 Biocompatibility Biocompatibility must be high, with resistance to thrombus formation, corrosion
and unwanted inﬂammatory or allergic reactions, and avoidance of neointimal
proliferation
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Table 2 Stenting applications in congenital heart disease.
Stenting localization Type of stents used most frequently Refs.
Stenting to improve efﬁciency of balloon
angioplasty
Lobar PA stenosis Formulaa, Valeob, Genesisc, Express Vasculard, coronary
stents, IntraStent Max LD
[20,22]
Main branch PA stenosis eV3 seriese, CP8-Zigf, Palmazc, Genesis, Andrastent XLg [17,23,30]
RVOT obstruction in neonates & infants
(palliative procedure)
Coronary & small peripheral bare-metal stents, Formula [22,46]
RVOT obstruction in children & adults Covered CP8-Zig, CP8-Zig, IntraStent Max LD, Palmaz,
Genesis
[17]
RV-to-PA conduit obstruction IntraStent Max LD, CP8-Zig, Palmaz, Genesis,
Andrastent XL
[17,56]
Fontan Tunnel obstruction IntraStent Max LD, CP8-Zig, Palmaz, Genesis,
Andrastent XL
PA rehabilitation in infants Formula, Valeo, Genesis [20,22,48]
Vena cava obstruction IntraStent Max LD, CP8-Zig, Palmaz, Genesis, Advanta
V12h
[17,63]
Postoperative or congenital PV stenosis Palmaz, Genesis, covered iCASTh, Valeo, coronary stents [33,63]
Stenting to improve safety of balloon
angioplasty
Aortic coarctation or Aortic recoarctation Covered CP8-Zig, CP8-Zig, IntraStent Max LD,
Andrastent XL, Palmaz, Genesis, covered Advanta V12
[7,15,17,63]
RVOT Covered CP8-Zig, CP8-Zig, IntraStent Max LD, Palmaz,
Genesis, Advanta V12
[17,63]
PA dissection or rupture Covered CP8-Zig, CP8-Zig, IntraStent Max LD, Palmaz,
Genesis
Mustard/Senning bafﬂe stenosis CP8-Zig, IntraStent Max LD, Andrastent XL, Palmaz,
Genesis
[23]
Stenting to close shunt
Fontan fenestration Covered CP8-Zig, Advanta V12 [35,63]
Potts shunt Covered CP8-Zig [37]
Mustard/Senning bafﬂe leaks Covered CP8-Zig [36]
Stenting to maintain shunt
Ductus Arteriosus Valeo, coronary & peripheral balloon-expandable
bare-metal stents, coronary & peripheral
self-expandable stents, Palmaz
[38—40,42]
Atrial septectomy Coronary balloon-expandable bare-metal stents [44]
Blalock-Taussig shunt Coronary balloon-expandable bare-metal stents,
drug-eluting coronary stents
[47]
Valved stent
Pulmonary regurgitation with RV dilation Melody valvei, Edwards-Sapien valvej [13,18,45]
RVOT obstruction Melody valve, Edwards-Sapien valve
RV-to-PA conduit Melody valve, Edwards-Sapien valve
‘Prestenting’ of the landing zone CP8-Zig, IntraStent Max LD, Palmaz, Genesis [45]
AC: aortic coarctation; AR: aortic recoarctation; DA: ductus arteriosus; FT: Fontan tunnel; PA: pulmonary artery; PV: pulmonary vein;
RV: right ventricle; RVOT: right ventricular outﬂow tract.
a Cook Europe, Bjaeverskov, Denmark.
b Bard Peripheral Vascular, Tempe, AZ, USA.
c Johnson & Johnson Interventional Systems, Warren, NJ, USA.
d Boston Scientiﬁc, Natick, MA, USA.
e eV3 Inc., Plymouth, MN, USA.
f Cheatham-PlatinumTM 8-Zig; NuMED Inc., Hopkinton, NY, USA.
g Andramed GmbH, Reutlingen, Germany.
h Atrium Medical Corporation, Hudson, NH, USA.
i Medtronic Inc., Minneapolis, MN, USA.
j Edwards Lifesciences LLC, Irvine, CA, USA.
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Figure 6. A. and B. A covered CP8Z45 stent implanted through a postsurgical superior vena cava (SVC) occlusion. C. A covered Cheatham-
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Stent mismatch
The stented vessel is unable to grow with the child, leading
to a relative restenosis of the vessel. Serial dilations of the
stents or surgical removal may be required, thus limiting
their use in this fast-growing population. Redilation with
a larger balloon is efﬁcient for increasing the diameter of
previously implanted balloon-expandable stents to accom-
modate somatic growth (Fig. 8) even with a covered CP
stent [24,53]. Fracturing a non-dilatable stent with a high-
pressure balloon is another solution for further expanding a
stent with vessel mismatch.
Vessel trauma
In native aortic coarctation stenting, aortic wall injury
occurs in < 1% of cases, particularly in Turner syndrome
[4,54], and occurs even less frequently after PA branch sten-
ting [6]. Such trauma may result in dissection, aneurysm
or even vessel rupture. Various interventional therapies
address these complications (coil or device occlusion of a PA
branch, implantation of a covered stent). Emergency surgery
is sometimes required [50].
Compression of adjacent structures
Stent implantation in vascular structures within the chest
in patients with CHD may induce mechanical compression
of surrounding structures. Coronary artery compression has
been described following transcatheter pulmonary valve
replacement and angioplasty of the right PA (Video 4)
[19,25]. Bronchial compression may also have disastrous
consequences [55].
P
B
B
dnestration. D. A CP stent positioned on a Mustard superior bafﬂe
l interatrial shunt. RA: right artery; RPA: right pulmonary artery;
ndocarditis
ndocarditis following stent implantation has been reported
arely [56]. However, since the introduction of valved stents
nd transcatheter pulmonary valve replacement, great con-
erns have been raised by reports suggesting endocarditis in
.88—2.4% of cases per year [57]. Risk factors and patholog-
cal mechanisms remain to be elucidated.
tent fractures
tent fractures are rare overall, observed in < 3% of cases
n patients with CHD [58]. Stent fractures mainly occur in
V-to-PA conduits, with an incidence ranging from 25 to
0% [47,56,58], and in both proximal PAs. In aortic coarc-
ation stenting, fractures have been observed in 8% of
ases [59]. In a single-centre report of 764 procedures, no
tent fracture was observed in any other location [58]. Inci-
ence also varies widely according to the type of stent
47]. Stent fractures may lead to distal fragment emboliza-
ion, but they are always asymptomatic. Stent fractures in
V-PA conduits are often associated with restenosis, which
ay lead to further transcatheter or surgical intervention.
herefore, this issue was an important concern when trans-
atheter pulmonary valve replacement was initiated, but
as resolved by prestenting the landing zone to increase its
adial strength before valve deployment (Figs. 3 and 4) [45].
erspectives
ioresorbable stents
ioresorbable stents have been developed, with the aim of
issolving after vessel healing, allowing the potential for
472 S. Hascoët et al.
Figure 7. A neonate (weight 3.6 kg) with a severe congenital mitral valve stenosis, a small left ventricle (Z score −3.5) and aortic arch
hypoplasia underwent a Norwood hybrid procedure. After bilateral pulmonary artery banding, in the operative room, ductus arteriosus (DA)
stenting was performed. A. Angiogram of the aorta (Ao) from an arterial femoral sheath. B. Angiogram of the DA (length 21mm). C. From
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. Final angiogram.
ate vessel remodelling and growth. Once the stent has dis-
ppeared, the vessel can grow with the child, eliminating
he need for future surgery or dilation. Bioresorbable stents
ay also facilitate future intervention in lesions with com-
lex anatomy, such as PA bifurcation lesions leading to jailed
essels. Bioresorbable stents would be of great value in
xtending interventional treatment of aortic coarctation or
ecoarctation in neonates and small children [27]. Precur-
or work involved a hybrid stent consisting of two metallic
alves connected by resorbable sutures implanted in small
hild’s recoarctation. This stent failed to follow the natural
rowth of the vessel, but was successfully redilated [60].
ioresorbable stents may also be valuable for the treatment
f PA stenosis in small children [61] and for the rehabilitation
f PA in tetralogy of Fallot with pulmonary atresia [48].
The manufacture of bioresorbable stents is challenging.
egradation time is a compromise between radial force and
l
T
t
Mpositioned and expanded into the DA; the Ao was voluntary jailed.
caffolding that allows vessel healing while degrading over
reasonable time for late vessel remodelling. Most avail-
ble bioresorbable stents have been developed for coronary
rtery treatment. Larger diameters are needed for use in
HD [62].
overed stents
he covered CP stent is used most frequently [35,36,53].
owever, the polytetraﬂuoroethylene membrane is fragile
nd can easily be damaged during stent crimping or stent
nsertion into the delivery sheath. Thus, the proﬁle is higher
nd larger sheaths are needed. The polytetraﬂuoroethy-
ene membrane is poorly compliant, with low ﬂexibility.
he covered CP stent can be dilated to a larger diame-
er [53,63]. The alternative AdvantaTM V12 stent (Atrium
edical Corporation, Hudson, NH, USA) has a better proﬁle
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Figure 8. A 4-year-old girl with type 3 tetralogy of Fallot with pulmonary atresia underwent sequential pulmonary artery rehabilitation and
complete surgical repair. Two Valeo stents (8mm diameter) were positioned on the left pulmonary artery (LPA) and on the main pulmonary
artery to the right pulmonary artery (RPA), jailing the LPA. After 4 years, right ventricular pressure was elevated due to bilateral pulmonary
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aartery restenosis. A.—C. Note the scaffolding defect that has favour
(12mm) successfully released the restenosis and further expanded
because the membrane is completely incorporated into the
inner and outer parts of a balloon-expandable stent. The
stent is premounted on a balloon until it reaches 16mm
and can be gently dilated up to 22mm, but with less
radial strength and more recoil. Thus, the ideal covered
stent for use in CHD remains to be developed. Associ-
ated with the evolution of stent frameworks and materials,
new synthetic and biological membrane components, such
as nanoparticles and ﬁbrin, may help to overcome these
issues [64].
Drug-eluting stents
Drug-eluting stents are coated with an antiproliferative drug
that decreases the risk of restenosis in coronary artery dis-
ease stenting. Drug-eluting stents are not currently useful in
CHD. However, the concept of using a stent as a platform for
substance delivery may be interesting. One may wonder if
stents coated with vessel growth factors would be useful in
the rehabilitation of PAs or in aortic arch hypoplasia, to pro-
mote the growth of small vessels. Moreover, in pulmonary
arterial hypertension, a drug-eluting stent coated with an
antihypertensive substance with progressive release of the
drug may be useful in increasing the in situ concentration.
This is not just a dream— illustrating this concept, Cabanelas
et al. used a drug-eluting stent coated on its endolumi-
nal surface by antihuman CD34 antibodies in children with
obstructed Blalock-Taussig shunt. This stent has endothelial
progenitor cell-capturing properties, promoting rapid cover-
age by endothelium, thus decreasing the risk of thrombosis
and restenosis [41].
t
l
m
ptrastent stenosis. B. and D. Postdilation with an Atlas Gold balloon
tents (D). RVOT: right ventricular outﬂow tract.
tent implantation imaging
he success of a stent procedure depends on the preci-
ion of the positioning. Deployment is a complex procedure
erformed under ﬂuoroscopic guidance with repeated
ngiograms. Modern ﬂuoroscopic angiography systems per-
it rendering of three-dimensional volumetric data sets
sing rotational angiography; along with magnetic reso-
ance imaging or multidetector-row computed tomography
atasets, they can be fused with live ﬂuoroscopy images
or road-mapping during therapeutic procedures. Glöckler
t al. recently observed that three-dimensional guidance
acilitates catheter-based interventions in CHD. Three-
imensional guidance simpliﬁes catheter manipulations and
nterventions, allows preselection of ideal projection angles
nd reduces ﬂuoroscopic time and the number of control
ngiograms [65].
onclusion
tents have contributed greatly to the development of inter-
entional catheterization for CHD. From the old rigid Palmaz
tent to covered and valved stents, technological evolu-
ion has further extended their clinical applications. The
nterventionists have to deal with the number and differ-
nt properties of available endoprostheses to choose the
ppropriate stent for each case. Results are good and sten-
ing has become a validated alternative to surgery in many
esions. Procedures can still be lengthy and complex but
ay be facilitated in many cases by fusion imaging and
erprocedural three-dimensional guidance. Large sheaths
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equired for stent deployment limit use and increase the
isk of vessel access complications. Miniaturization of deliv-
ry systems would facilitate implantation in tortuous and
mall vessels. The inability of stents to follow natural ves-
el growth remains an important limitation to their use in
rowing children. Biodegradable stents with sufﬁcient radial
trength but respecting natural vessel growth may further
xtend the use in infants and neonates.
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